Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Conditions
Brief summary
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the growth of cancer cells by blocking some of the proteins needed for cell growth. Pomalidomide may help shrink or slow the growth of multiple myeloma. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving isatuximab, carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.
Detailed description
OUTLINE: INDUCTION: Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide orally (PO) once daily (QD) on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity. All patients undergo bone marrow aspirate and biopsy during screening, skeletal x-ray, computed tomography (CT), positron emission tomography (PET)-CT, or magnetic resonance imaging (MRI), bone marrow and blood sample collection throughout the study. After completion of study treatment, patients are followed up at 30 days, then for up to 5 years.
Interventions
DRUGCarfilzomib
Given IV
DRUGDexamethasone
Given PO or IV
BIOLOGICALIsatuximab
Given IV
DRUGPomalidomide
Given PO
PROCEDUREBone Marrow Biopsy
Undergo bone marrow biopsy
PROCEDUREBone Marrow Aspiration
Undergo bone marrow aspiration
PROCEDURESkeletal Survey X-Ray
Undergo skeletal x-ray
PROCEDUREComputed Tomography
Undergo CT
PROCEDUREPositron Emission Tomography
Undergo PET-CT
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
Sponsors
University of Washington
Genzyme, a Sanofi Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with relapsed or refractory multiple myeloma, with \>= 1 prior therapy * Must have received prior lenalidomide therapy * Must have measurable disease, as defined by International Myeloma Working Group criteria, having one or more of the following: * Serum M protein \>= 0.5 g/dL * Urine M protein \>= 200 mg/24 hours * Involved serum free light chain level \>= 10 mg/dL with abnormal kappa/lambda ratio * Measurable biopsy-proven plasmacytomas (\>= 1 lesion has a single diameter \>= 2 cm) * Bone marrow plasma cells \>= 30% * Age 18 years and older, and have the capacity to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Subjects should have resolution of any toxicities from prior therapy to grade =\< 1 or baseline prior to enrollment (with the exception of peripheral neuropathy) * Subjects are required to have grade =\< 2 peripheral neuropathy to enroll * Prior autologous stem cell transplant is allowed; patients must be \>= 6 months post- autologous stem cell transplantation to enroll * Estimated glomerular filtration rate (eGFR) \>= 20 ml/min * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x upper limit of normal (ULN) * Total bilirubin =\< 2 x ULN * Absolute neutrophil count (ANC) \>= 1,000/uL * Platelets \>= 50,000/uL * Hemoglobin \>= 8 g/dL * Growth factor use or transfusions may be used to meet the eligibility requirement for ANC, platelets, and hemoglobin * Female patients of childbearing potential and male patients must agree to use 2 effective forms of contraception or continuously abstain from heterosexual intercourse during the period of therapy, and for 6 months after discontinuation of study treatment for females and 3 months after discontinuation of study treatment for males
Exclusion criteria
* History of clinically significant cardiovascular disease, including congestive heart failure New York Heart Association (NYHA) class 3-4, symptomatic ischemia, left ventricular ejection fraction \< 40%, uncontrolled conduction abnormalities, myocardial infarction in last 6 months * Uncontrolled hypertension as determined by the principal investigator (PI) or designee * Active plasma cell leukemia or systemic amyloid light-chain (AL) amyloidosis * History of another primary malignancy that has not been in remission for at least 1 year * However, the following diagnoses are eligible for inclusion: non-melanoma skin cancer, localized prostate cancer, superficial bladder cancer, cervical carcinoma in situ, on biopsy or any prior malignancy with an estimated \> 90% 1-year cure rate per sponsor-investigator * For patients with chronic hepatitis B viral infection, the hepatitis B virus (HBV) polymerase chain reaction (PCR) must be undetectable on suppressive therapy * Patients with a history of Hepatitis C viral infection must have been treated and cured. For patients on treatment for hepatitis C, they are eligible if they have an undetectable hepatitis C virus (HCV) viral load * Subjects with active uncontrolled infection * Concurrent use of other anticancer agents or experimental treatments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall response rate | Up to 5 years post treatment | Responses will be based on the International Myeloma Working Group criteria for response in multiple myeloma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From first study drug administration to the first occurrence of disease progression or death from any cause, assessed up to 5 years | PFS will be calculated using assessments by investigators. Kaplan-Meier methodology will be used to estimate event-free curves and corresponding quartiles (including the median). |
| Overall survival | From the first study drug administration to death from any cause, assessed up to 5 years | Kaplan-Meier methodology will be used to estimate the event-free curves. |
| Duration of response | Up to 5 years post treatment | — |
| Time to progression | Up to 5 years post treatment | — |
| Incidence of adverse events | Up to 30 days post treatment | Will be measured by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
| Rates of minimal residual disease negativity | Up to 5 years post treatment | Measured by next-generation sequencing of immunoglobulin genes in the bone marrow. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRahul Banerjee, MD
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed